secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001104659-24-071337
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

TransCode shareholders reject reverse stock split; stock plan amendment approved
--------------------------------------------------------------------------------

- Reverse stock split (1:2 to 1:40) failed: 1,018,164 for, 1,277,915 against, 96,498 abstain.
- Stock plan amendment passed: 526,212 for, 205,773 against; adds 3,000,000 shares for issuance.
- All four director nominees elected (Calais, Fitzgerald, Manting, Marquet) with ~595K-597K votes for.
- Auditor WithumSmith+Brown ratified: 2,193,452 for, 159,569 against, 39,556 abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924071337/0001104659-24-071337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924071337/tm2417255d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-071337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer